$BIORQ
BIORA THERAPEUTICS, INC.

2024 Q1 Form 10-K Financial Statement

#000095017024039423 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $542.0K $0.00 $4.000K
YoY Change 27000.0% -100.0% -99.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.053M $7.226M $37.31M
YoY Change 8.34% -9.93% -1.91%
% of Gross Profit
Research & Development $7.005M $6.118M $29.84M
YoY Change -2.57% 6.09% 24.07%
% of Gross Profit
Depreciation & Amortization $105.0K $115.0K $600.0K
YoY Change 5.0% -27.22% -33.33%
% of Gross Profit
Operating Expenses $16.06M $13.34M $67.15M
YoY Change 3.29% -3.23% 8.15%
Operating Profit -$15.52M -$67.14M
YoY Change -0.18% 8.68%
Interest Expense $2.757M $10.89M $9.815M
YoY Change 2.87% 292.82% -10.69%
% of Operating Profit
Other Income/Expense, Net $217.0K -$13.28M -$65.47M
YoY Change -367.9% 501.54% -2601.72%
Pretax Income -$4.141M -$15.73M -$124.4M
YoY Change -76.26% 19.05% 152.64%
Income Tax $48.00K -$95.00K -$90.00K
% Of Pretax Income
Net Earnings -$4.200M -$15.41M -$124.1M
YoY Change -75.86% 12.32% 224.87%
Net Earnings / Revenue -774.91% -3102500.0%
Basic Earnings Per Share -$0.14 -$7.87
Diluted Earnings Per Share -$0.14 -$0.63 -$7.87
COMMON SHARES
Basic Shares Outstanding 30.31M 23.70M 15.77M
Diluted Shares Outstanding 29.30M 15.77M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.82M $15.21M $15.21M
YoY Change -64.48% -50.1% -50.1%
Cash & Equivalents $10.60M $15.00M $15.21M
Short-Term Investments
Other Short-Term Assets $169.0K $587.0K $3.030M
YoY Change -45.31% 3.89% -55.45%
Inventory
Prepaid Expenses $2.260M $2.443M
Receivables
Other Receivables
Total Short-Term Assets $14.07M $19.07M $19.07M
YoY Change -62.14% -49.97% -49.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.136M $1.156M $2.770M
YoY Change -24.17% -30.11% -11.67%
Goodwill $6.072M $6.072M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $3.000M $3.000M
YoY Change -100.0% -50.0% -50.0%
Other Assets $293.0K $3.302M $302.0K
YoY Change -95.32% -46.75% 50.25%
Total Long-Term Assets $8.919M $12.14M $12.14M
YoY Change -44.52% -21.19% -21.19%
TOTAL ASSETS
Total Short-Term Assets $14.07M $19.07M $19.07M
Total Long-Term Assets $8.919M $12.14M $12.14M
Total Assets $22.99M $31.22M $31.22M
YoY Change -56.82% -41.68% -41.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.936M $2.843M $2.843M
YoY Change 44.24% -21.16% -21.16%
Accrued Expenses $14.87M $14.56M $14.56M
YoY Change -8.98% 3.51% 3.51%
Deferred Revenue $0.00 $542.0K
YoY Change -100.0% 1053.19%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.976M $1.976M $1.976M
YoY Change
Total Short-Term Liabilities $51.10M $62.97M $62.97M
YoY Change 103.74% 170.21% 170.21%
LONG-TERM LIABILITIES
Long-Term Debt $43.28M $43.74M $43.74M
YoY Change -66.24% -65.78% -65.78%
Other Long-Term Liabilities $2.583M $3.029M $25.93M
YoY Change -48.06% -35.5% 452.13%
Total Long-Term Liabilities $2.583M $3.029M $69.66M
YoY Change -48.06% -35.5% -47.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.10M $62.97M $62.97M
Total Long-Term Liabilities $2.583M $3.029M $69.66M
Total Liabilities $123.2M $132.6M $132.6M
YoY Change -22.16% -14.87% -14.87%
SHAREHOLDERS EQUITY
Retained Earnings -$955.1M -$951.0M
YoY Change 13.12% 15.02%
Common Stock $874.0M $868.6M
YoY Change 15.25% 16.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$100.2M -$101.4M -$101.4M
YoY Change
Total Liabilities & Shareholders Equity $22.99M $31.22M $31.22M
YoY Change -56.82% -41.68% -41.68%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.200M -$15.41M -$124.1M
YoY Change -75.86% 12.32% 224.87%
Depreciation, Depletion And Amortization $105.0K $115.0K $600.0K
YoY Change 5.0% -27.22% -33.33%
Cash From Operating Activities -$12.50M -$13.75M -$48.50M
YoY Change 3.31% 24.79% -24.69%
INVESTING ACTIVITIES
Capital Expenditures $15.00K $63.00K $103.0K
YoY Change -6.25% -12.5% -86.99%
Acquisitions
YoY Change
Other Investing Activities $3.020M $2.536M $2.546M
YoY Change 30100.0%
Cash From Investing Activities $3.005M $2.473M $2.443M
YoY Change -50183.33% -3534.72% -408.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $18.14M
YoY Change 101.21%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.100M 13.92M 30.78M
YoY Change -57.78% 208.26% 321.77%
NET CHANGE
Cash From Operating Activities -12.50M -13.75M -48.50M
Cash From Investing Activities 3.005M 2.473M 2.443M
Cash From Financing Activities 5.100M 13.92M 30.78M
Net Change In Cash -4.391M 2.645M -15.28M
YoY Change 18991.3% -140.23% -73.62%
FREE CASH FLOW
Cash From Operating Activities -$12.50M -$13.75M -$48.50M
Capital Expenditures $15.00K $63.00K $103.0K
Free Cash Flow -$12.52M -$13.81M -$48.60M
YoY Change 3.29% 24.54% -25.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001580063
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20231231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20231231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20231231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2023 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2024-04-01
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39334
CY2023 dei Entity Registrant Name
EntityRegistrantName
BIORA THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3950390
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4330 La Jolla Village Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
CY2023 dei City Area Code
CityAreaCode
833
CY2023 dei Local Phone Number
LocalPhoneNumber
727-2841
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
BIOR
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
38960310
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30313428
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
830000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
828000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2603000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19071000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38116000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1654000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1614000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1482000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6201000
CY2023Q4 us-gaap Goodwill
Goodwill
6072000
CY2022Q4 us-gaap Goodwill
Goodwill
6072000
CY2023Q4 us-gaap Assets
Assets
31215000
CY2022Q4 us-gaap Assets
Assets
53525000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2843000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3606000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2022Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16161000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
40834000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3538000
CY2023Q4 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
1976000
CY2022Q4 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
0
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62972000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23305000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
127811000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2023Q4 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
19179000
CY2022Q4 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
0
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22899000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4696000
CY2023Q4 us-gaap Liabilities
Liabilities
132636000
CY2022Q4 us-gaap Liabilities
Liabilities
155812000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28574918
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9098844
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27837563
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8928498
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
868591000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
743626000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-950958000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-826843000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
737355
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170346
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19079000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19078000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31215000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53525000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29838000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24049000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37309000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38037000
CY2023 us-gaap Operating Expenses
OperatingExpenses
67147000
CY2022 us-gaap Operating Expenses
OperatingExpenses
62086000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-67143000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-61781000
CY2023 us-gaap Interest Expense
InterestExpense
9815000
CY2022 us-gaap Interest Expense
InterestExpense
10990000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18004000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20904000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65470000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2617000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-124424000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49250000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-90000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-420000
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-124334000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-48830000
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
219000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
10673000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124115000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-38157000
CY2023 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.88
CY2023 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.88
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.4
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.4
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.01
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.01
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
1.4
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
1.4
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.87
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.87
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15773297
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15773297
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7635107
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7635107
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-84976000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9282000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
98000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-267000
CY2022 bior Stock Issued During Period Value Conversion Of Interests Net
StockIssuedDuringPeriodValueConversionOfInterestsNet
3929000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7804000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-38157000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17488000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1960000
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
67431000
CY2023 bior Related Party Troubled Debt Restructuring
RelatedPartyTroubledDebtRestructuring
25547000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16475000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124115000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124115000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-38157000
CY2023 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
219000
CY2022 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
10673000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
555000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
907000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
16475000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7804000
CY2023 bior Loss On Extinguishment Of Convertible Notes And Accrued Interest
LossOnExtinguishmentOfConvertibleNotesAndAccruedInterest
-6363000
CY2022 bior Loss On Extinguishment Of Convertible Notes And Accrued Interest
LossOnExtinguishmentOfConvertibleNotesAndAccruedInterest
-2722000
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1601000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1419000
CY2023 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
53198000
CY2022 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-543000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
100000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
545000
CY2023 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
3915000
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18004000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20904000
CY2023 us-gaap Gain Loss On Investments
GainLossOnInvestments
-3000000
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
5731000
CY2023 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
2000
CY2022 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
828000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-998000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3387000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1172000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5072000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10677000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-417000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1884000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1720000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48499000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-66175000
CY2023 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0
CY2022 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
1758000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48499000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64417000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
103000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
792000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-92000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-792000
CY2023 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
2535000
CY2022 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2443000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-792000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18137000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9014000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3318000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1960000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
98000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10000000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2023 bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
2264000
CY2022 bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
5120000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1132000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023 bior Principal Payments On Capital Lease Obligations
PrincipalPaymentsOnCapitalLeaseObligations
0
CY2022 bior Principal Payments On Capital Lease Obligations
PrincipalPaymentsOnCapitalLeaseObligations
12000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30781000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7298000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15275000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-57911000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88397000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2277000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5871000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
18000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
31000
CY2023 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
51000000
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2023 bior Related Party Troubled Debt Restructuring
RelatedPartyTroubledDebtRestructuring
25547000
CY2022 bior Related Party Troubled Debt Restructuring
RelatedPartyTroubledDebtRestructuring
0
CY2023 bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
18000000
CY2022 bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
0
CY2023 bior Conversion Of Accrued Interest In Exchange For Senior Secured Convertible Notes
ConversionOfAccruedInterestInExchangeForSeniorSecuredConvertibleNotes
6953000
CY2022 bior Conversion Of Accrued Interest In Exchange For Senior Secured Convertible Notes
ConversionOfAccruedInterestInExchangeForSeniorSecuredConvertibleNotes
0
CY2023 bior Enumera Molecular Investment In Exchange For Assets
EnumeraMolecularInvestmentInExchangeForAssets
0
CY2022 bior Enumera Molecular Investment In Exchange For Assets
EnumeraMolecularInvestmentInExchangeForAssets
6000000
CY2023 bior Issuance Of Common Stock And Re Priced Warrants Upon Settlement Of Accrued Interest
IssuanceOfCommonStockAndRePricedWarrantsUponSettlementOfAccruedInterest
0
CY2022 bior Issuance Of Common Stock And Re Priced Warrants Upon Settlement Of Accrued Interest
IssuanceOfCommonStockAndRePricedWarrantsUponSettlementOfAccruedInterest
3929000
CY2023 bior Issuance Of Warrants Upon Settlement Of Accrued Interest
IssuanceOfWarrantsUponSettlementOfAccruedInterest
0
CY2022 bior Issuance Of Warrants Upon Settlement Of Accrued Interest
IssuanceOfWarrantsUponSettlementOfAccruedInterest
2300000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1344000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2922000
CY2023 bior Change In Fair Value Of Re Priced Equity Classified Warrants
ChangeInFairValueOfRePricedEquityClassifiedWarrants
0
CY2022 bior Change In Fair Value Of Re Priced Equity Classified Warrants
ChangeInFairValueOfRePricedEquityClassifiedWarrants
619000
CY2023 bior Equity Offering Costs Incurred But Not Paid
EquityOfferingCostsIncurredButNotPaid
49000
CY2022 bior Equity Offering Costs Incurred But Not Paid
EquityOfferingCostsIncurredButNotPaid
116000
CY2023 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
350000
CY2022 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2023 bior Issuance Of Common Stock In Settlement In Accrued Expenses
IssuanceOfCommonStockInSettlementInAccruedExpenses
0
CY2022 bior Issuance Of Common Stock In Settlement In Accrued Expenses
IssuanceOfCommonStockInSettlementInAccruedExpenses
98000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
86000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15000000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
200000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-951000000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124100000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the valuation of stock options, the valuation of goodwill, the valuation of the derivative liabilities associated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with the 2028 Convertible Notes, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, the valuation of assets held for sale, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
200000
CY2022Q4 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
0
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
100000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
500000
CY2023 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Embedded Derivatives Related to Convertible Notes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Company issued the 2028 Convertible Notes with embedded derivatives that are required to be bifurcated from the host contract and remeasured to fair value at each balance sheet date. Any resulting gain or loss related to the change in the fair value of the embedded derivatives are recorded to other income, net in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 bior Minimum Percentage Of Recognized Income Tax Positions
MinimumPercentageOfRecognizedIncomeTaxPositions
0.50
CY2023 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2023 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1219000
CY2022 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
11848000
CY2023 bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
1000000
CY2022 bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
1175000
CY2023 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1000000
CY2022 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1175000
CY2023 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
219000
CY2022 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
10673000
CY2023Q4 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
2800000
CY2023Q4 bior Cost Incurred In Sale Of Property Plant And Equipment
CostIncurredInSaleOfPropertyPlantAndEquipment
200000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2000000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2443000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3634000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
587000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
565000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3263000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5653000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2107000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3999000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1654000
CY2023 us-gaap Depreciation
Depreciation
600000
CY2022 us-gaap Depreciation
Depreciation
900000
CY2023Q4 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
302000
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
201000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6201000
CY2023Q4 bior Accrual For Reimbursement Claims And Legal Settlements Current
AccrualForReimbursementClaimsAndLegalSettlementsCurrent
6337000
CY2022Q4 bior Accrual For Reimbursement Claims And Legal Settlements Current
AccrualForReimbursementClaimsAndLegalSettlementsCurrent
8372000
CY2023Q4 bior Commission And Bonus Current
CommissionAndBonusCurrent
2469000
CY2022Q4 bior Commission And Bonus Current
CommissionAndBonusCurrent
1433000
CY2023Q4 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1367000
CY2022Q4 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1724000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2914000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
307000
CY2023Q4 bior Accrued Interest Current
AccruedInterestCurrent
173000
CY2022Q4 bior Accrued Interest Current
AccruedInterestCurrent
890000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
896000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
893000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
401000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
445000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
542000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
47000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2220000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2050000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2022Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16161000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
818000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
601000
CY2023Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
2211000
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
4095000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4696000
CY2022Q4 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2023Q4 bior Related Party Senior Secured Convertible Notes
RelatedPartySeniorSecuredConvertibleNotes
21155000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000000
bior Class Of Warrant Or Right Period For Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable
after September 18, 2023 until September 18, 2026
CY2023Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
53200000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35100000
CY2023 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
25500000
CY2023 bior Troubled Debt Restructuring Debtor Future Interest Payments Capitalized
TroubledDebtRestructuringDebtorFutureInterestPaymentsCapitalized
11700000
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.3
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3018868
CY2023Q2 bior Common Stock Ownership Percentage
CommonStockOwnershipPercentage
0.05
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
96.78
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
763012
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.23
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1369000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1531000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1281000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1609000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1022000
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
590000
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
264000
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
18000
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1894000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
180000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1714000
CY2020Q3 bior Number Of States Participating In Settlement
NumberOfStatesParticipatingInSettlement
45
CY2023Q3 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
1700000
CY2021Q3 bior Aggregate Amount Of Historical Payments
AggregateAmountOfHistoricalPayments
5700000
CY2021Q4 bior Aggregate Amount Of Historical Payments
AggregateAmountOfHistoricalPayments
3300000
CY2022 bior Claim Settlement Amount Refunded
ClaimSettlementAmountRefunded
11000000
CY2023 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
200000
CY2020Q4 bior Aggregate Amount Of Historical Payments
AggregateAmountOfHistoricalPayments
27400000
CY2023Q4 bior Payor Recoupment
PayorRecoupment
1100000
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2023 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
1000000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 3, 2023, the Company effected a 1-for-25 reverse stock split of the Company's common stock.
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1300250
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6000000
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1600000
CY2022Q4 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
800000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
900000
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
5.3
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3018868
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.05
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7300000
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
CY2023Q2 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-1000000
CY2023Q2 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1000000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4278074
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.93
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.87
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
9900000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6700000
CY2023Q4 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-6700000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
48475911
CY2022Q4 bior Number Of Vote Per Preferred Stock Held
NumberOfVotePerPreferredStockHeld
3000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
582557
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.89
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
265000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.54
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
84545
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
200
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
763012
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
36.23
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
200
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
269718
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
66.98
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.047
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.02
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.976
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.027
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.907
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.013
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.49
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.09
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16475000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7804000
CY2023 bior Income Tax Reconciliation Extinguishment Loss
IncomeTaxReconciliationExtinguishmentLoss
1336000
CY2022 bior Income Tax Reconciliation Extinguishment Loss
IncomeTaxReconciliationExtinguishmentLoss
0
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6600000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-546000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-15000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-347000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
126000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-15000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-767000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-75000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
347000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-75000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
347000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-90000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-420000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-26129000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10343000
CY2023 bior Income Tax Reconciliation Cancellation Of Debt
IncomeTaxReconciliationCancellationOfDebt
8161000
CY2022 bior Income Tax Reconciliation Cancellation Of Debt
IncomeTaxReconciliationCancellationOfDebt
0
CY2023 bior Income Tax Reconciliation Inducement Loss
IncomeTaxReconciliationInducementLoss
11172000
CY2022 bior Income Tax Reconciliation Inducement Loss
IncomeTaxReconciliationInducementLoss
0
CY2023 bior Income Tax Reconciliation Convertible Debt
IncomeTaxReconciliationConvertibleDebt
-3781000
CY2022 bior Income Tax Reconciliation Convertible Debt
IncomeTaxReconciliationConvertibleDebt
-4390000
CY2023 bior Income Tax Reconciliation Derivative Liability
IncomeTaxReconciliationDerivativeLiability
822000
CY2022 bior Income Tax Reconciliation Derivative Liability
IncomeTaxReconciliationDerivativeLiability
0
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2687000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1504000
CY2023 bior Effective Income Tax Rate Reconciliation Tax Refunds
EffectiveIncomeTaxRateReconciliationTaxRefunds
-35000
CY2022 bior Effective Income Tax Rate Reconciliation Tax Refunds
EffectiveIncomeTaxRateReconciliationTaxRefunds
-900000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5556000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13004000
CY2023 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
121000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
705000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-90000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-420000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
139735000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
137149000
CY2023Q4 bior Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
7536000
CY2022Q4 bior Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
4027000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
656000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
949000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1159000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
527000
CY2023Q4 bior Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
360000
CY2022Q4 bior Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
343000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1460000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2591000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
101000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
150906000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
145687000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
222000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
726000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
1110000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
1201000
CY2023Q4 bior Deferred Tax Liabilities Investment In Enumera
DeferredTaxLiabilitiesInvestmentInEnumera
574000
CY2022Q4 bior Deferred Tax Liabilities Investment In Enumera
DeferredTaxLiabilitiesInvestmentInEnumera
1317000
CY2023Q4 bior Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
339000
CY2022Q4 bior Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
340000
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
271000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
743000
CY2023Q4 bior Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
0
CY2022Q4 bior Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
552000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2516000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4879000
CY2023Q4 bior Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
148390000
CY2022Q4 bior Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
140808000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
148649000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141155000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
259000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
347000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7500000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
500300000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
218600000
CY2023Q4 bior Percentage Of Taxable Income Use Of Federal Net Operating Loss Carry Forwards
PercentageOfTaxableIncomeUseOfFederalNetOperatingLossCarryForwards
0.80
CY2023 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
CY2023 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
78108406
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4815813
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
500000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
500000
CY2023 dei Auditor Firm
AuditorFirmId
185

Files In Submission

Name View Source Status
0000950170-24-039423-index-headers.html Edgar Link pending
0000950170-24-039423-index.html Edgar Link pending
0000950170-24-039423.txt Edgar Link pending
0000950170-24-039423-xbrl.zip Edgar Link pending
bior-20231231.htm Edgar Link pending
bior-20231231.xsd Edgar Link pending
bior-ex10_29.htm Edgar Link pending
bior-ex21_1.htm Edgar Link pending
bior-ex23_1.htm Edgar Link pending
bior-ex31_1.htm Edgar Link pending
bior-ex31_2.htm Edgar Link pending
bior-ex32_1.htm Edgar Link pending
bior-ex4_23.htm Edgar Link pending
bior-ex4_24.htm Edgar Link pending
bior-ex4_25.htm Edgar Link pending
bior-ex4_8.htm Edgar Link pending
bior-ex4_9.htm Edgar Link pending
bior-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img189307841_0.jpg Edgar Link pending
img189307841_1.jpg Edgar Link pending
img189307841_2.jpg Edgar Link pending
img189307841_3.jpg Edgar Link pending
img189307841_4.jpg Edgar Link pending
img189307841_5.jpg Edgar Link pending
img189307841_6.jpg Edgar Link pending
img189307841_7.jpg Edgar Link pending
img189307841_8.jpg Edgar Link pending
img43358358_0.jpg Edgar Link pending
img43358358_1.jpg Edgar Link pending
img43358358_2.jpg Edgar Link pending
img43358358_3.jpg Edgar Link pending
img43358358_4.jpg Edgar Link pending
img43358358_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bior-20231231_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending